Project Grant R21AR087354
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $408K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
- Federal Project Grant Award Summary The University of Alabama at Birmingham received a $1.34 million Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective September 1, 2025, through August 31, 2028. The grant supports a three-year research investigation into the mechanisms of delayed lung injury following exposure to trivalent arsenic chemical agents, including lewisite, phenyl arsenic...
- The National Institutes of Health Office of the Director awarded The Johns Hopkins University $247,337 on August 18, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate glutamine metabolism and vesicant pathogenesis in response to NOFO-PA-25-093. The project will characterize the metabolic consequences of nitrogen mustard and phenylarsine oxide exposure in keratinocytes using in vivo mouse models of skin exposure, performing untargeted imaging mass spectrometry for...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $2.576 million on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct integrated research targeting the cGAS-STING pathway in autoimmune and inflammatory disease. The program assembles a team with complementary expertise in immunology, structural biology, medicinal chemistry, proteomics, and pharmacology to investigate the...
- The National Institutes of Health Office of the Director awarded Michigan State University (operating as Henry Ford Health+Michigan State University Health Sciences) $1,403,056 under the Trans-NIH Research Support program (CFDA 93.310) on April 23, 2026, to identify mechanisms of lung toxicity from skin exposure to vesicants. The recipient will conduct research establishing the role of mast cells and delineating mechanisms of acute and long-term lung toxicity from dermal exposure to mustard...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $984,124 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for advancement of BCG-STING, a recombinant Bacillus Calmette-Guerin vaccine candidate engineered to overexpress a STING agonist as a next-generation tuberculosis vaccine. The project funds development and testing of BCG-STING to improve upon the efficacy and safety profile of conventional BCG vaccine....
- The National Institutes of Health Office of the Director awarded the University of Tennessee Health Science Center $403,972 under the Trans-NIH Research Support program (CFDA 93.310) on August 15, 2026, to define mechanistic pathways through which arsenic trioxide disrupts brain and cognitive function and to identify novel therapeutic strategies to prevent or mitigate delayed neurotoxic consequences of exposure. Research focuses on the integrated stress response and stimulator of interferon...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded $902,741 to the University of Washington on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds basic research into the cell type-specific regulation of STING signaling, a central pathway in innate immune response with implications for antiviral immunity, antitumor immunity, and aging-associated inflammation. The research investigates why STING activation produces...
- The National Institute of Allergy and Infectious Diseases awarded the University of Alabama at Birmingham $223,500 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate Group A Streptococcus-induced autoimmune complexes and post-streptococcal sequelae. The research examines the autoimmune mechanisms underlying post-streptococcal disorders including rheumatic heart disease, rheumatic fever, post-strep arthritis, post-strep...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded the University of Alabama at Birmingham $409,750 on July 2, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate the therapeutic potential of NPS-2143 as a treatment for chlorine-induced lung edema. The award supports research demonstrating that inhibition of the calcium-sensing receptor using the calcilytic NPS-2143, administered after chlorine exposure, prevents...
- The National Institute of Allergy and Infectious Diseases awarded the University of Southern California $456,500 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and apply photochemical crosslinking technology for identifying immune-activation DNA ligands that bind the cGAS protein in living cells. The research addresses the transient and weak nature of cGAS–DNA interactions, which conventional crosslinking methods fail to capture. Aim 1...